Haracec Complete Healthcare
- Vitamin IV Therapy
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
El Paso, TX
Ketamine Therapy clinics in El Paso
Ketamine therapy in El Paso is delivered through psychiatry-led clinics, anesthesia-run infusion centers, and ketamine-assisted psychotherapy practices, with hospital referrals often tied to Texas Tech Physicians and University Medical Center of El Paso. Demand reflects a border, Hispanic-majority, Medicaid-heavy population and an active local market for treatment-resistant depression, PTSD, and chronic pain.
The strongest evidence supports intranasal esketamine (Spravato, FDA-approved for treatment-resistant depression) and intravenous racemic ketamine (off-label, substantial supporting evidence). Clinics in El Paso, Texas also offer intramuscular, sublingual, and at-home oral lozenge protocols, with weaker evidence and variable safety oversight. Texas Medical Board and cross-border pharmacy considerations shapes which clinics can operate as cash-pay versus insurance-eligible.
With ketamine clinics on Regenerated.com in El Paso, patients can compare whether the clinic offers psychiatric evaluation, anesthesia monitoring during infusion, and structured preparation and integration.
IV DR. well and hydration
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- IV Hydration
- Ketamine Therapy
Donya Pain and Wellness Center
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- Ketamine Therapy
- Arthritis Treatment
Prime IV Hydration & Wellness
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- IV Hydration
Diamond Hormone Replacement Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- IV Hydration
- Ketamine Therapy
Donya Pain and Wellness Center
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- Ketamine Therapy
- Arthritis Treatment
Regulatory context
A note on Texas's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
HB 1802 / Psilocybin and MDMA Research (2021)
Required Texas Health and Human Services Commission to study psilocybin and MDMA for PTSD treatment in veterans; report completed. -
Texas Ibogaine Initiative (HB 3717, 2025 pending)
Would allocate $50 million for FDA-regulated ibogaine clinical trials, potentially the largest state psychedelic research investment in US history. -
Texas Controlled Substances Act
Mirrors federal scheduling.
Texas enforces federal scheduling. The Texas Medical Board oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Texas PMP requires controlled substance reporting. Texas has seen rapid ketamine clinic growth in Austin, Dallas, and Houston markets with corresponding enforcement attention on compounding and telehealth practices.